Top in allergy/asthma: Epinephrine spray action date; COVID-19 vaccine safety finding
Click Here to Manage Email Alerts
The FDA has set a new target action date for ARS Pharmaceuticals’ neffy epinephrine nasal spray, which is designed to treat anaphylaxis and other type 1 allergic reactions without a needle or injection.
The new action date has been extended to Sept. 19.
“We are hopeful that labeling discussions will be completed as soon as possible given the significant unmet need in the allergy community for a needle-free option that is easily carried and administered without anxiety or hesitation,” Richard Lowenthal,MS, MSEL (MBA), cofounder, president and CEO of ARS Pharmaceuticals, said in a press release.
It was the top story in allergy/asthma last week.
Another top story was about a research letter on the safety of COVID-19 vaccination among six children with prior reactions and four children with pre-existing conditions that increase their risk for a reaction. Researchers concluded that nine out of the 10 children could now safely receive a messenger RNA COVID-19 vaccine.
Read these and more top stories in allergy/asthma below:
FDA extends target action date for epinephrine nasal spray to September
The FDA has extended the prescription drug user fee act target action date for the new drug application for neffy intranasal epinephrine spray from ARS Pharmaceuticals to Sept. 19, according to a company press release. Read more.
COVID-19 vaccination safe in children with prior reactions, pre-existing conditions
Children with a history of allergy to COVID-19 vaccines or pre-existing conditions that put them at higher risk for a reaction safely tolerated testing and challenges, according to a letter published in Clinical and Translational Allergy. Read more.
Air pollution associated with length of hospital stays in pediatric asthma in the Bronx
Ambient particulate matter at the 2.5 µm scale and ozone pollution were associated with longer hospital stays for pediatric patients with asthma in the Bronx, according to a study published in Journal of Asthma. Read more.
Sebum transcriptome data predict development of atopic dermatitis in young infants
Molecular changes in barrier function and inflammatory markers characterized the pathophysiology of atopic dermatitis at age 1 month, according to a study published in the Journal of the European Academy of Dermatology and Venereology. Read more.
AAAAI-funded research to probe new discoveries in EoE, interferon signaling
Researchers will study connections between eosinophilic esophagitis and interferon signaling, possibly paving the way for new treatments, with funding from the AAAAI Foundation’s 2023 Faculty Development awards. Read more.